Benefits and Safety of Tirofiban Among Acute Coronary Syndrome Patients With Mild to Moderate Renal Insufficiency: Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial
Circulation - United States
doi 10.1161/01.cir.0000016359.94919.16
Full Text
Open PDFAbstract
Available in full text
Date
May 21, 2002
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)